Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Halo Pharma Announces Investment and Formal Collaboration with Altus

Published: Thursday, May 16, 2013
Last Updated: Thursday, May 16, 2013
Bookmark and Share
Halo Pharma has taken a minority ownership position in, and established a formal collaboration with, Altus Formulation Inc.

Altus uses proprietary technologies and approaches to solve pharmaceutical formulation and delivery problems.

Halo is focused on satisfying the pharmaceutical client's development and manufacturing needs, whether those needs are straightforward or complex. On a fee for service basis Halo will always remain committed to practical facilitation and implementation of non proprietary and client based solutions to scientific and technical challenges in the areas of pre-formulation, analytical method development, formulation, scale up, regulatory submission and commercial manufacturing. These approaches typically generate significant new wholly client owned IP.

With this new investment in, and association with, Altus Formulations, Halo takes a first step in offering to clients, when needed, an entire suite of proprietary scientific and technical solutions designed to solve intractable issues in such areas as drug solubility, bioavailability, tamper and abuse deterrence, and precisely managed drug dosage delivery. These proprietary solutions cover a wide range of non-sterile and sterile dosage forms. One such area requiring solution is the currently much discussed question of the need for abuse resistance for narcotic analgesic and other frequently abused CNS drugs.

In commenting on the collaboration with Altus the CEO of Halo Pharma Clive Bennett said, "We are delighted to have this new association with Altus as it will allow Halo to provide novel proprietary solutions to clients with difficult formulation problems in addition to those already available public domain and client originated solutions that we have historically offered."

Damon Smith CEO of Altus Formulation remarked, "The Altus team is extremely excited to be collaborating with Halo Pharma with their track record of excellence in the contract development and manufacturing fields. By combining our strengths Altus and Halo offer a full range of development and delivery options that are ideally placed to meet the needs of the industry."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos